cis-dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-arboxamides:: synthesis and action in resistant cell lines in vitro

被引:57
作者
Holmes, RJ
McKeage, MJ
Murray, V
Denny, WA
McFadyen, WD
机构
[1] Univ Melbourne, Sch Chem, Parkville, Vic 3052, Australia
[2] Univ Auckland, Sch Med, Auckland, New Zealand
[3] Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia
[4] Univ Auckland, Auckland Canc Soc Res Ctr, Fac Med & Hlth Sci, Auckland 1, New Zealand
基金
英国医学研究理事会;
关键词
cis-dichloroplatinum(II); 9-aminoacridine-4-carboxamides; synthesis; cytotoxicity; resistance;
D O I
10.1016/S0162-0134(01)00188-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A series of intercalator-tethered platinum(II) complexes PtLCl2 have been prepared where L are the diamine ligands N-[2-[(aminoethyl)amino]ethyl]-9-aminoacridine N-[3-[(2-aminoethyl)amino]propyl]-9-aminoacridine-4-carboxamide, N-[4-[(2-aminoethyl)amino]butyl]-9-aminoacridine-34-carboxamide and N-[5-[(aminoethyl)amino]pentyl]-9-aminoacridine-4-carboxmide and N-[6-[(aminoethyl)amino]hexyl]-9-aminoacridine-4-carboxamide. The activity of the complexes was assessed in the CH-1, CH-1cisR, 41M, 41McisR and SKOV-3 cell lines. The compounds with the shorter linker chain lengths are generally the most active against these cell lines and are much more toxic than Pt(en)Cl-2. For example, Tor the n=2 compound the IC50 values are 0.017 muM (CH-1), 1.7 muM (41M), 1.4 muM (SKOV-3) and the resistance ratios are 51 (CH-1cisR) and 1.6 (41McisR). For the untethered analogue Pt(en)Cl-2 the IC50 values are 2.5 muM (CH-1), 2.9 muM (41M), 45 muM (SKOV-3) and the resistance ratios are 2.8 (CH-1cisR) and 4.1 (41McisR). The very large differential in IC,, values between the CH-1 and CH-1cisR pair of cell lines for the 9-aminoacridine-4-carboxamide tethered platinum complexes indicates that repair of platinum-induced DNA damage may be a major determinant of the activity of these compounds. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 29 条
[1]
[Anonymous], 1983, J IMMUNOL METH
[2]
POTENTIAL ANTITUMOR AGENTS .43. SYNTHESIS AND BIOLOGICAL-ACTIVITY OF DIBASIC 9-AMINOACRIDINE-4-CARBOXAMIDES, A NEW CLASS OF ANTITUMOR AGENT [J].
ATWELL, GJ ;
CAIN, BF ;
BAGULEY, BC ;
FINLAY, GJ ;
DENNY, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (11) :1481-1485
[3]
COMPARISON OF INVIVO AND INVITRO DRUG SENSITIVITIES OF LEWIS LUNG-CARCINOMA AND P388-LEUKEMIA TO ANALOGS OF AMSACRINE [J].
BAGULEY, BC ;
WILSON, WR .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (06) :607-613
[4]
DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent [J].
Brabec, V ;
Kaspárková, J ;
Vrána, O ;
Nováková, O ;
Cox, JW ;
Qu, Y ;
Farrell, N .
BIOCHEMISTRY, 1999, 38 (21) :6781-6790
[5]
PHASE-I STUDY OF OXALIPLATIN IN PATIENTS WITH ADVANCED CANCER [J].
EXTRA, JM ;
ESPIE, M ;
CALVO, F ;
FERME, C ;
MIGNOT, L ;
MARTY, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (04) :299-303
[6]
CARBOXYLATION OF KINETICALLY INERT PLATINUM(IV) HYDROXY COMPLEXES - AN ENTREE INTO ORALLY-ACTIVE PLATINUM(IV) ANTITUMOR AGENTS [J].
GIANDOMENICO, CM ;
ABRAMS, MJ ;
MURRER, BA ;
VOLLANO, JF ;
RHEINHEIMER, MI ;
WYER, SB ;
BOSSARD, GE ;
HIGGINS, JD .
INORGANIC CHEMISTRY, 1995, 34 (05) :1015-1021
[7]
PREPARATION, CHARACTERIZATION, AND ANTICANCER ACTIVITY OF A SERIES OF CIS-PTCL2 COMPLEXES LINKED TO ANTHRAQUINONE INTERCALATORS [J].
GIBSON, D ;
GEAN, KF ;
BENSHOSHAN, R ;
RAMU, A ;
RINGEL, I ;
KATZHENDLER, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (01) :414-420
[8]
THE ROLE OF MURINE TUMOR-MODELS AND THEIR ACQUIRED PLATINUM-RESISTANT COUNTERPARTS IN THE EVALUATION OF NOVEL PLATINUM ANTITUMOR AGENTS - A CAUTIONARY NOTE [J].
GODDARD, PM ;
VALENTI, MR ;
HARRAP, KR .
ANNALS OF ONCOLOGY, 1991, 2 (08) :535-540
[9]
HARRAP KR, 1983, CANC CHEMOTHERAPY, pCH7
[10]
BIOLOGICAL PROPERTIES OF 10 HUMAN OVARIAN-CARCINOMA CELL-LINES - CALIBRATION INVITRO AGAINST 4 PLATINUM COMPLEXES [J].
HILLS, CA ;
KELLAND, LR ;
ABEL, G ;
SIRACKY, J ;
WILSON, AP ;
HARRAP, KR .
BRITISH JOURNAL OF CANCER, 1989, 59 (04) :527-534